SUBSCRIBE
SUBSCRIBE
BioCapital

Pfizer Inc., Boehringer Ingelheim Corporation’s Spiriva May Raise Risk of Stroke Says US FDA

March 19, 2008 | 
1 min read

WASHINGTON (Reuters) - The lung drug Spiriva, marketed by Pfizer Inc and Boehringer Ingelheim Pharmaceutical Inc, may increase the risk of stroke, the U.S. Food and Drug Administration said on Tuesday.

Pfizer Boehringer Ingelheim Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
 · 
4 min read
 · 
Lorenzo Soliman
Pictured: Man holding tablet computer with scienti
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Again Rejects Supernus Drug-Device Combo for Parkinson’s Disease
April 8, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: 3d illustration of hepatitis B viruses i
Drug Development
Altimmune Axes Hepatitis B Program After Phase II Failure, Focuses on Obesity and MASH
March 28, 2024
 · 
1 min read
 · 
Tyler Patchen